CN104997742B - Bilobanone ester dropping pills and preparation method thereof - Google Patents
Bilobanone ester dropping pills and preparation method thereof Download PDFInfo
- Publication number
- CN104997742B CN104997742B CN201510378999.8A CN201510378999A CN104997742B CN 104997742 B CN104997742 B CN 104997742B CN 201510378999 A CN201510378999 A CN 201510378999A CN 104997742 B CN104997742 B CN 104997742B
- Authority
- CN
- China
- Prior art keywords
- bilobanoate
- macrogol
- medicinal substrate
- peg
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of bilobanone ester dropping pills, and including Bilobanoate and medicinal substrate, the weight percent of the two is 10%~18%:82%~90%；The medicinal substrate is by Macrogol 4000, Macrogol 6000 and PEG 8000 by weight 3~5:1~1.3:0.4~0.7 is formed；Also disclose the preparation method of the dripping pill.The present invention is made of Bilobanoate with medicinal substrate according to special ratios, and medicinal substrate is that the polyethylene glycol of three kinds of different molecular weights mixes so that the disintegration rate of this bilobanone ester dropping pills is fast, and disintegration time is 6~10 minutes；Make to act on human body in the drug effect short time, release the slight illness of patient.
Description
Technical field
The present invention relates to a kind of dropping pill formulations and preparation method thereof, especially bilobanone ester dropping pills and preparation method thereof.
Background technology
After pill refers to that solid or liquid medicine dissolve mixing with matrix heating, instill in not miscible condensate liquid,
It shrinks and condenses and manufactured preparation；Matrix generally comprises water-soluble base and water-insoluble base, common to have polyethylene glycol
6000th, gelatin and stearic acid etc.；Condensate liquid must be safe and harmless, common to have liquid paraffin, vegetable oil, methyl-silicone oil and water
Deng.
Cardiovascular and cerebrovascular disease has the characteristics that high incidence, high mortality and high disability rate, is that the No.1 of human health kills
Hand.It is mainly as the main component with Bilobanoate that the sick drug is treated at present, is had using pill as treatment cardiovascular and cerebrovascular disease
Disease；But existing bilobanone ester dropping pills disintegration time in stomach and intestine is long, and generally 15~18 minutes, for being badly in need of solving disease
Caused pain, patient is allowed, which to endure, seems that this time is more long.
The patent application CN200610113450.7 and CN201010112227.7 proposed before applicant reports ginkgo
Ketone ester dropping pill preparation, but cannot be satisfactory in terms of dissolution rate, disintegration time limited, appearance as the dripping pill obtained by it, always
It can not solve the problems, such as that patient's is painful.Therefore, in dropping pill formulation field particularly Bilobanoate field, to improved dissolution
The dripping pill product of the properties such as degree, disintegration time limited, appearance has urgent and lasting needs.
The content of the invention
In view of the deficiencies of the prior art, the present invention proposes a kind of new bilobanone ester dropping pills preparations, and disintegration time is short, from
And effectively mitigate patient's burden.
In order to realize foregoing invention purpose, one aspect of the present invention provides following bilobanone ester dropping pills：It includes Bilobanoate
And medicinal substrate, the weight percent of the two is 10%~18%:82%~90%；The medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 3~5:1~1.3:0.4~0.7 is formed.
Another aspect of the present invention provides the method for preparing bilobanone ester dropping pills, and this method comprises the following steps：
(1), by 10%~18%:82%~90% weight ratio takes Bilobanoate and medicinal substrate, the medicinal substrate by
Macrogol 4000, Macrogol 6000 and polyethylene glycol-800 are by weight 3~5:1~1.3:0.4~0.7 is formed；
(2) Bilobanoate, is crossed into 100~150 mesh sieves；
(3), by Macrogol 4000, Macrogol 6000 and PEG 8000 mixing, 70~85 DEG C are heated to, stir,
Heat preservation 2~3 minutes；The Bilobanoate (2) step is sieved after is added in, is stirred evenly；
(4), (3) mixture instills in condensate liquid into dripping pill step.
Preferably, the weight percent of the Bilobanoate and medicinal substrate is 13%~15%:85%~87%.
Preferably, the weight percent of the Bilobanoate and medicinal substrate is 14%:86%.
Preferably, in the medicinal substrate Macrogol 4000, Macrogol 6000 and PEG 8000 weight ratio
For 4~5:1.2~1.3:0.6~0.7.
Preferably, in the medicinal substrate Macrogol 4000, Macrogol 6000 and PEG 8000 weight ratio
For 4.5:1.2:0.6.
Preferably, (3) middle Bilobanoate adds in speed as 12~15 gram/minutes to step.
Preferably, the mixture after (3) step stirs evenly continues in 60~65 DEG C of heat preservations.
Preferably, the condensate liquid is one kind or more in atoleine, methyl-silicone oil, dimethicone or vegetable oil
Kind.
Preferably, Bilobanoate crosses 120~130 mesh sieves.
Compared with prior art, the present invention has the following advantages.Medicinal substrate in bilobanone ester dropping pills be by three kinds not
Polyethylene glycol with molecular weight mixes in specific proportions.Applicants have unexpectedly found that such medicinal substrate is used to cause this
Faster, specific disintegration time is 6 to the bilobanone ester dropping pills that invention bilobanone ester dropping pills disintegration rate is obtained than in the prior art
~10 minutes；Make to act on human body in the drug effect short time, release the slight illness of patient.
Specific embodiment
With reference to embodiment, the present invention will be described in detail, the description of this part be only it is exemplary and explanatory, no
Reply protection scope of the present invention has any restriction effect.
Bilobanoate with polyethylene glycol is dissolved, is suspended, is emulsified into molecule or micro- using solid dispersion technology by the present invention
Grain.Polyethylene glycol is crystallinity water soluble (CO) polymers, the helix in molecule in per unit there are two unit, when drug cures
When, Bilobanoate is may be embodied in just in the spiral shape interstitial space of polyethylene glycol, and the two forms chromic fibrous solid solution；
During polyethylene glycol is dissolved in water so that the Bilobanoate being dispersed therein is dissolved, so as to improve Bilobanoate
Solubility and dissolution rate.
After the dispersion of polyethylene glycol-drug cools down rapidly in condensate liquid, when low temperature, cures within a very short time, utilizes
Dripping pill is made in polyethylene glycol-Bilobanoate dispersion by this characteristic, can expand the surface area of drug, improves the suction of Bilobanoate
Speed and bioavilability are received, is played the role of quick-acting and efficient.
The present invention is using Macrogol 4000, the poly- second of three kinds of different molecular weights of Macrogol 6000 and PEG 8000
Glycol, the mixed-matrix each formed using specific composition scope is as medicinal substrate；When Bilobanoate exists in specific proportions
When curing in the medicinal substrate, substantial amounts of Bilobanoate can be included in the spiral shape interstitial space of the medicinal substrate, and silver can be made
The dissolution rate of apricot ketone ester is accelerated.Wherein, the weight percent of Bilobanoate and medicinal substrate is 10%~18%:82%~
90%, and medicinal substrate is by Macrogol 4000, Macrogol 6000 and PEG 8000 by weight 3~5:1~1.3:
0.4~0.7 is formed, and the dissolution rate of Bilobanoate is very fast；Preferably, the weight percent of Bilobanoate and medicinal substrate is
13%~15%:85%~87%；Optimal, the weight percent of Bilobanoate and medicinal substrate is 14%:86%.
Preferred scheme is the weight ratio of Macrogol 4000, Macrogol 6000 and PEG 8000 in medicinal substrate
For 4~5:1.2~1.3:0.6~0.7；Optimal, Macrogol 4000, Macrogol 6000 and polyethylene glycol in medicinal substrate
8000 weight ratio is 4.5:1.2:0.6.
Offer table 1 of the present invention is used to illustrate influence of the different medicinal substrate schemes to bilobanone ester dropping pills product property.
1 medicinal substrate of table screens
In addition, when preparing bilobanone ester dropping pills, sieving processing is carried out to the Bilobanoate raw material for adding in mixed-matrix, is selected
It can be further contained in the spiral shape interstitial space of mixed-matrix with the Bilobanoate of appropriate particle size, it is molten to form chromic fibrous solid-state
Liquid.Wherein, Bilobanoate crosses that 100~150 mesh sieves are more suitable, and more preferably, Bilobanoate crosses 120~130 mesh sieves.
Embodiment
The applicant provides following embodiments to illustrate the product of the present invention and method, but institute in claims
The technical solution of restriction from following embodiments limitation.
Embodiment 1
(1), each component is weighed in following ratios：10g Bilobanoates and 90g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 3:1.3:0.4 is formed；
(2), Bilobanoate crosses 150 mesh sieves；
(3), Macrogol 4000, Macrogol 6000 and PEG 8000 mixing are heated in rustless steel container
70 DEG C, stirring, heat preservation 3 minutes；The Bilobanoate (2) step is sieved after is added in, addition speed is 12 gram/minutes, is stirred evenly, and is continued
In 65 DEG C of heat preservations；
(4), dripping condition：Water dropper bore 3.5mm/4.5mm is dripped away from 6-8cm, adjusts dropping liquid valve (drop speed about per minute 50
Drop), by step, (3) mixture is instilled in the condensate liquid of 16 DEG C of atoleines, and dripping pill 1000 is made.
Embodiment 2
(1), each component is weighed in following ratios：18g Bilobanoates and 82g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 5:1:0.7 is formed；
(2), Bilobanoate crosses 100 mesh sieves；
(3), Macrogol 4000, Macrogol 6000 and PEG 8000 mixing are heated in rustless steel container
85 DEG C, stirring, heat preservation 2 minutes；The Bilobanoate (2) step is sieved after is added in, addition speed is 15 gram/minutes, is stirred evenly, and is continued
In 60 DEG C of heat preservations；
(4), dripping condition：Water dropper bore 3.5mm/4.5mm is dripped away from 6-8cm, adjusts dropping liquid valve (drop speed about per minute 50
Drop), by step, (3) mixture is instilled in the condensate liquids of 13 DEG C of methyl-silicone oils into dripping pill 1000.
Embodiment 3
(1), each component is weighed in following ratios：15g Bilobanoates and 85g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 4:1.3:0.6 is formed；
(2), Bilobanoate crosses 130 mesh sieves；
(3), Macrogol 4000, Macrogol 6000 and PEG 8000 mixing are heated in rustless steel container
78 DEG C, stirring, heat preservation 2 minutes；The Bilobanoate (2) step is sieved after is added in, addition speed is 13 gram/minutes, is stirred evenly, and is continued
In 62 DEG C of heat preservations；
(4), dripping condition：Water dropper bore 3.5mm/4.5mm is dripped away from 6-8cm, adjusts dropping liquid valve (drop speed about per minute 50
Drop), by step, (3) mixture is instilled in 17 DEG C of atoleines and dimethicone condensation by mixing liquid into dripping pill 1000.
Embodiment 4
(1), each component is weighed in following ratios：1g Bilobanoates and 88g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 5:1.2:0.7 is formed；
(2), Bilobanoate crosses 120 mesh sieves；
(3), Macrogol 4000, Macrogol 6000 and PEG 8000 mixing are heated in rustless steel container
73 DEG C, stirring, heat preservation 3 minutes；The Bilobanoate (2) step is sieved after is added in, addition speed is 12 gram/minutes, is stirred evenly, and is continued
In 62 DEG C of heat preservations；
(4), dripping condition：Water dropper bore 3.5mm/4.5mm is dripped away from 6-8cm, adjusts dropping liquid valve (drop speed about per minute 50
Drop), by step, (3) mixture is instilled in the condensate liquids of 20 DEG C of vegetable oil into dripping pill 1000.
Embodiment 5
(1), each component is weighed in following ratios：14g Bilobanoates and 86g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 4.5:1.2:0.6 is formed；
(2), Bilobanoate crosses 125 mesh sieves；
(3), Macrogol 4000, Macrogol 6000 and PEG 8000 mixing are heated in rustless steel container
82 DEG C, stirring, heat preservation 2.5 minutes；The Bilobanoate (2) step is sieved after is added in, addition speed is 14 gram/minutes, is stirred evenly, after
Continue in 64 DEG C of heat preservations；
(4), dripping condition：Water dropper bore 3.5mm/4.5mm is dripped away from 6-8cm, adjusts dropping liquid valve (drop speed about per minute 50
Drop), by step, (3) mixture is instilled in the condensate liquids of 14 DEG C of atoleines into dripping pill 1000.
The dripping pill product sampling that above-described embodiment 1-5 is prepared to gained carries out following experiments.
Pill weight variation measuring method
Reference《Chinese Pharmacopoeia》One I K of annex of version in 2010 is checked that take dripping pill 20, accurately weighed total weight is removed
With 20, average ball weight is obtained.From 20 grain balls of weighed total weight, 1 is taken out successively, accurately weighed weight, obtains respectively respectively
Dripping pill weight.Calculated weight difference.Dripping pill hardness measurement method：Judged with hand to pinch.
Disintegration time limited measuring method
Reference《Chinese Pharmacopoeia》Method under one annex of version in 2010, Ⅻ A disintegration time limited inspection technique items, the disintegration to dripping pill
Time limit is checked, dripping pill 6 is taken, by official method inspection.
Appearance roundness test method:Gross visualization
Test result such as the following table 2：
Table 2
In order to more clearly show the advantage of the medicinal substrate of the present invention, applicant carried out following contrast tests and in table
Result of the test is provided in 3.
Comparative example 1
(1), each component is weighed in following ratios：15g Bilobanoates and 85g medicinal substrates, medicinal substrate is by polyethylene glycol
4000 and Macrogol 6000 by weight 3:1 is formed；
Step (2), (3) and (4) distinguishes step (2), (3) and (4) as described in example 3 above.
Comparative example 2
(1), each component is weighed in following ratios：15g Bilobanoates and 85g medicinal substrates, medicinal substrate is by polyethylene glycol
4000 and Macrogol 6000 by weight 2:1 is formed；
Step (2), (3) and (4) distinguishes step (2), (3) and (4) as described in example 3 above.
Embodiment 6
(1), each component is weighed in following ratios：15g Bilobanoates and 85g medicinal substrates, medicinal substrate is by polyethylene glycol
4000th, Macrogol 6000 and PEG 8000 are by weight 4.5:1.2:0.6 is formed；
Step (2), (3) and (4) distinguishes step (2), (3) and (4) as described in example 3 above
The bilobanone ester dropping pills sampling that above-mentioned experiment is obtained carries out pill weight variation, dripping pill hardness and disintegration time limited test,
Test result such as table 3.
Table 3
It summarizes, through the detection to above-mentioned all embodiment products, it is known that Bilobanoate uses special ratios with medicinal substrate,
And medicinal substrate is the bilobanone ester dropping pills that the polyethylene glycol of three kinds of different molecular weights mixes in specific proportions, mouldability
Good, dripping is smooth, and dripping pill is smooth, mellow and full, and disintegration rate is fast, is 6~10 minutes, so as to make to act in the drug effect short time
In human body, the slight illness of patient is released.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of bilobanone ester dropping pills, it is characterised in that：Including Bilobanoate and medicinal substrate, wherein the Bilobanoate and medicine
It is 13%~15% with the weight percent of matrix:85%~87%；The medicinal substrate is by Macrogol 4000, polyethylene glycol
6000 and PEG 8000 by weight 4~5:1.2~1.3:0.6~0.7 is formed.
2. bilobanone ester dropping pills as described in claim 1, it is characterised in that：The weight percent of the Bilobanoate and medicinal substrate
Than for 14%:86%.
3. bilobanone ester dropping pills as described in claim 1, it is characterised in that：Macrogol 4000, poly- second in the medicinal substrate
The weight ratio of glycol 6000 and PEG 8000 is 4.5:1.2:0.6.
4. a kind of method for preparing bilobanone ester dropping pills described in claim 1, the described method comprises the following steps：
(1), by 13%~15%:85%~87% weight ratio takes Bilobanoate and medicinal substrate, and the medicinal substrate is by poly- second
Glycol 4000, Macrogol 6000 and PEG 8000 are by weight 4~5:1.2~1.3:0.6~0.7 is formed；
(2) Bilobanoate, is crossed into 100~150 mesh sieves；
(3), by Macrogol 4000, Macrogol 6000 and PEG 8000 mixing, 70~85 DEG C are heated to, stirring, heat preservation
2~3 minutes；The Bilobanoate (2) step is sieved after is added in, is stirred evenly；
(4), by step, (3) mixture is instilled in condensate liquid into dripping pill.
5. method as claimed in claim 4, it is characterised in that：The weight percent of the Bilobanoate and medicinal substrate is
14%:86%.
6. method as claimed in claim 4, it is characterised in that：Macrogol 4000, polyethylene glycol in the medicinal substrate
6000 and PEG 8000 weight ratio be 4.5:1.2:0.6.
7. method as claimed in claim 4, it is characterised in that：It is 12~15 Grams Per Minutes that Bilobanoate, which adds in speed, in step (3)
Clock.
8. method as claimed in claim 4, it is characterised in that：Mixture (3) step stirs evenly after continues in 60~65 DEG C of guarantors
Temperature.
9. method as claimed in claim 4, it is characterised in that：The condensate liquid is atoleine, methyl-silicone oil or vegetable oil
In one or more.
10. method as claimed in claim 4, it is characterised in that：Bilobanoate crosses 120~130 mesh sieves.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510378999.8A CN104997742B (en) | 2015-07-01 | 2015-07-01 | Bilobanone ester dropping pills and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510378999.8A CN104997742B (en) | 2015-07-01 | 2015-07-01 | Bilobanone ester dropping pills and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104997742A CN104997742A (en) | 2015-10-28 |
| CN104997742B true CN104997742B (en) | 2018-05-29 |
Family
ID=54370791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510378999.8A Active CN104997742B (en) | 2015-07-01 | 2015-07-01 | Bilobanone ester dropping pills and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104997742B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113491672B (en) * | 2020-04-07 | 2022-11-29 | 成都百裕制药股份有限公司 | A dripping pill containing bilobalide as effective component and its preparation method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552319A (en) * | 2003-06-05 | 2004-12-08 | 许启太 | Ginkgo ketonic ester dripping pill |
| CN1651007A (en) * | 2004-12-27 | 2005-08-10 | 李宏 | Ginkgo ketone ester drop pill and its preparation method |
| CN1931160A (en) * | 2006-09-28 | 2007-03-21 | 北京汉典中西药研究开发中心 | Ginkgo ketone ester dropping pill and its prepn process |
| CN101791323A (en) * | 2006-09-28 | 2010-08-04 | 北京汉典中西药研究开发中心 | Ginkgo biloba extract dripping pill and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050037094A1 (en) * | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
-
2015
- 2015-07-01 CN CN201510378999.8A patent/CN104997742B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552319A (en) * | 2003-06-05 | 2004-12-08 | 许启太 | Ginkgo ketonic ester dripping pill |
| CN1651007A (en) * | 2004-12-27 | 2005-08-10 | 李宏 | Ginkgo ketone ester drop pill and its preparation method |
| CN1931160A (en) * | 2006-09-28 | 2007-03-21 | 北京汉典中西药研究开发中心 | Ginkgo ketone ester dropping pill and its prepn process |
| CN101791323A (en) * | 2006-09-28 | 2010-08-04 | 北京汉典中西药研究开发中心 | Ginkgo biloba extract dripping pill and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 滴丸基质和冷凝介质的概况;程宇慧;《医药工业》;19881231;第19卷(第11期);第521-523页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104997742A (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elkhodairy et al. | Formulation and optimization of orodispersible tablets of flutamide | |
| US9446137B2 (en) | Composite particles which contain both cellulose and inorganic compound | |
| Jadhav et al. | Formulation and evaluation of dispersible tablets of diltiazem hydrochloride | |
| JPWO2006115198A1 (en) | Porous cellulose aggregate and molded body composition thereof | |
| CN101961316B (en) | LID-PEG-PLGA controlled-release nano microsphere and preparation method thereof | |
| Patil et al. | Formulation and evaluation of orally disintegrating tablet containing tramadol hydrochloride by mass extrusion technique | |
| de Farias et al. | Microencapsulation of riboflavin with galactomannan biopolymer and F127: Physico-chemical characterization, antifungal activity and controlled release | |
| CN102655752A (en) | Solid pharmaceutical compositions containing an integrase inhibitor | |
| Ikoni | Some physicochemical properties of acetaminophen pediatric suspensions formulated with okra gums obtained from different extraction processes as suspending agent | |
| JP7332549B2 (en) | How to suppress mount occurrence | |
| Avachat et al. | Characterization and Evaluation of Spray Dried Co-Processed Excipients and Their Application in Solid Dosage Forms. | |
| CN104997742B (en) | Bilobanone ester dropping pills and preparation method thereof | |
| Khan et al. | Optimization of diluents on the basis of SeDeM-ODT expert system for formulation development of ODTs of glimepiride | |
| Zaman et al. | Synthesis and characterization of thiol modified beta cyclodextrin, its biocompatible analysis and application as a modified release carrier of ticagrelor | |
| Eraga et al. | Evaluation of fast disintegrating tablets of paracetamol prepared from a blend of croscarmellose sodium and Pleurotus tuber-regium powder | |
| Untari et al. | Physical Interaction of Chitosan-Alginate Entrapping Extract of Papaya Leaf and Formation of Submicron Particles Dosage form: New Dossage form to Inhibit The Dengue Diseases | |
| Olajide | Physicochemical properties of some paediatric and adult products of dihydroartemisinin-piperaquine antimalarial marketed in Nigeria | |
| EP3572436A1 (en) | Highly dispersible dextrin and production method therefor | |
| WO2021090421A1 (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| Ghori et al. | Formulation and In-vitro evaluation of Orodispersible tablets of Telmisartan | |
| Assefa et al. | Formulation, Optimization and | |
| Rajpurohit et al. | Hordeum vulgare hull in the design of fast disintegrating tablets | |
| Akpabio et al. | Investigating Corchorus olitorius hydrocolloid as a novel matrix former in sustained release delivery of ibuprofen tablet | |
| CN103052381A (en) | Composition comprising shellac and/or a salt thereof and sodium starch glycolate | |
| Paudel et al. | Formulation and in-vitro evaluation of bupropion hydrochloride controlled release tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |